首页> 外文OA文献 >Enhancing Biopharmaceutical Attributes of Phospholipid Complex-loaded Nanostructured Lipidic Carriers of Mangiferin: Systematic Development, Characterization and Evaluation
【2h】

Enhancing Biopharmaceutical Attributes of Phospholipid Complex-loaded Nanostructured Lipidic Carriers of Mangiferin: Systematic Development, Characterization and Evaluation

机译:增强磷脂复合物负载的芒果甙纳米结构脂质载体的生物制药属性:系统开发,表征和评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mangiferin (Mgf), largely expressed out from the leaves and stem bark of Mango, is a potent antioxidant. However, its in vivo activity gets tremendously reduced owing to poor aqueous solubility and inconsistent gastrointestinal absorption, high hepatic first-pass metabolism and high P-gp efflux. The current research work, therefore, was undertaken to overcome the biopharmaceutical hiccups by developing the Mgf-phospholipid complex (PLCs) loaded in nanostructured lipidic carriers (NLCs). The PLCs and NLCs were prepared using refluxing, solvent evaporation and hot emulsification technique, respectively with various molar ratios of Mgf and Phospholipon 90 G, i.e., 1:1; 1:2; and 1:3. The complex was evaluated for various physicochemical parameters like drug content (96.57%), aqueous solubility (25-fold improved) and oil-water partition coefficient (10-fold enhanced). Diverse studies on the prepared complex using FTIR, DSC, PXRD and SEM studies ratified the formation of PLCs at 1:1 ratio. The PLCs were further incorporated onto NLCs, which were systematically optimized employing a face centered cubic design (FCCD), while evaluating for particle size, zeta potential, encapsulation efficiency and in vitro drug release as the CQAs. Caco-2 cell line indicated insignificant cytotoxicity, and P-gp efflux, bi-directional permeability model and in situ perfusion studies specified enhanced intestinal permeation parameters. In vivo pharmacokinetic studies revealed notable increase in the values of Cmax (4.7-fold) and AUC (2.1-fold), respectively, from PLCs-loaded NLCs vis-à-vis Mgf solution. In a nutshell, the promising results observed from the present research work signified boosted biopharmaceutical potential of the optimized PLCs-loaded NLCs for potentially augmenting the therapeutic efficacy of Mgf.
机译:Mangiferin(Mgf)主要从芒果的叶子和茎皮中表达出来,是一种有效的抗氧化剂。然而,由于水溶性差和胃肠道吸收不一致,肝首过代谢高以及P-gp外排高,其体内活性大大降低。因此,当前的研究工作是通过开发装载在纳米结构脂质载体(NLC)中的Mgf-磷脂复合物(PLC)来克服生物制药的难题。使用回流,溶剂蒸发和热乳化技术制备PLC和NLC,分别以不同的Mgf和Phospholipon 90 G的摩尔比,即1:1; 1:2;和1:3。对复合物的各种理化参数进行了评估,例如药物含量(96.57%),水溶性(提高了25倍)和油水分配系数(提高了10倍)。使用FTIR,DSC,PXRD和SEM研究制备的复合物的各种研究证实了PLC以1:1的比例形成。将PLC进一步整合到NLC中,这些NLC使用面心立方设计(FCCD)进行了系统优化,同时评估了粒径,ζ电位,包封效率和体外药物释放(作为CQA)。 Caco-2细胞系显示出微不足道的细胞毒性,P-gp外排,双向通透性模型和原位灌注研究指定了增强的肠渗透参数。体内药代动力学研究表明,相对于Mgf溶液,装有PLC的NLC分别使Cmax(4.7倍)和AUC(2.1倍)值显着增加。简而言之,从本研究工作中观察到的有希望的结果表明,优化的装载PLC的NLC潜在地增强了Mgf的治疗功效,具有增强的生物制药潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号